A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, L. Leichman, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. RadfordL. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, W. A. Messersmith

Research output: Contribution to journalArticle

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)2505
Number of pages1
JournalAnnals of Oncology
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

O'Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Leichman, L., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J., Coveler, L., Olowokure, O. O., Baranda, J. C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D. J., ... Messersmith, W. A. (2015). A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]. Annals of Oncology, 26(12), 2505. https://doi.org/10.1093/annonc/mdv477